Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity - PubMed (original) (raw)
. 2000 Sep 1;96(5):1953-60.
Affiliations
- PMID: 10961900
Free article
Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity
T Michigami et al. Blood. 2000.
Free article
Abstract
Myeloma is a unique hematologic malignancy that exclusively homes in the bone marrow and induces massive osteoclastic bone destruction presumably by producing cytokines that promote the differentiation of the hematopoietic progenitors to osteoclasts (osteoclastogenesis). It is recognized that neighboring bone marrow stromal cells influence the expression of the malignant phenotype in myeloma cells. This study examined the role of the interactions between myeloma cells and neighboring stromal cells in the production of osteoclastogenic factors to elucidate the mechanism underlying extensive osteoclastic bone destruction. A murine myeloma cell line 5TGM1, which causes severe osteolysis, expresses alpha(4)beta(1)-integrin and tightly adheres to the mouse marrow stromal cell line ST2, which expresses the vascular cell adhesion molecule-1 (VCAM-1), a ligand for alpha(4)beta(1)-integrin. Co-cultures of 5TGM1 with primary bone marrow cells generated tartrate-resistant acid phosphatase-positive multinucleated bone-resorbing osteoclasts. Co-cultures of 5TGM1 with ST2 showed increased production of bone-resorbing activity and neutralizing antibodies against VCAM-1 or alpha(4)beta(1)-integrin inhibited this. The 5TGM1 cells contacting recombinant VCAM-1 produced increased osteoclastogenic and bone-resorbing activity. The activity was not blocked by the neutralizing antibody to known osteoclastogenic cytokines including interleukin (IL)-1, IL-6, tumor necrosis factor, or parathyroid hormone-related peptide. These data suggest that myeloma cells are responsible for producing osteoclastogenic activity and that establishment of direct contact with marrow stromal cells via alpha(4)beta(1)-integrin/VCAM-1 increases the production of this activity by myeloma cells. They also suggest that the presence of stromal cells may provide a microenvironment that allows exclusive colonization of myeloma cells in the bone marrow. (Blood. 2000;96:1953-1960)
Similar articles
- Chinese hamster ovary cells expressing alpha4beta1 integrin stimulate osteoclast formation in vitro.
Akatsu T, Ono K, Murakami T, Katayama Y, Nishikawa M, Wada S, Yamamoto M, Kugai N, Matsuura N, Takada Y, Nagata N. Akatsu T, et al. J Bone Miner Res. 1998 Aug;13(8):1251-9. doi: 10.1359/jbmr.1998.13.8.1251. J Bone Miner Res. 1998. PMID: 9718193 - Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis.
Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams PJ, Mundy GR, Yoneda T. Mori Y, et al. Blood. 2004 Oct 1;104(7):2149-54. doi: 10.1182/blood-2004-01-0236. Epub 2004 May 11. Blood. 2004. PMID: 15138161 - Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.
Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T. Abe M, et al. J Bone Miner Metab. 2009;27(1):16-23. doi: 10.1007/s00774-008-0012-z. Epub 2008 Dec 5. J Bone Miner Metab. 2009. PMID: 19057841 - VLA-4-dependent myeloma cell adhesion.
Sanz-Rodríguez F, Teixidó J. Sanz-Rodríguez F, et al. Leuk Lymphoma. 2001 Apr;41(3-4):239-45. doi: 10.3109/10428190109057979. Leuk Lymphoma. 2001. PMID: 11378537 Review. - VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells.
Oostendorp RA, Dörmer P. Oostendorp RA, et al. Leuk Lymphoma. 1997 Feb;24(5-6):423-35. doi: 10.3109/10428199709055581. Leuk Lymphoma. 1997. PMID: 9086434 Review.
Cited by
- Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications.
Baldessari C, Pipitone S, Molinaro E, Cerma K, Fanelli M, Nasso C, Oltrecolli M, Pirola M, D'Agostino E, Pugliese G, Cerri S, Vitale MG, Madeo B, Dominici M, Sabbatini R. Baldessari C, et al. Cancers (Basel). 2023 Feb 28;15(5):1518. doi: 10.3390/cancers15051518. Cancers (Basel). 2023. PMID: 36900309 Free PMC article. Review. - A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments.
Hervás-Salcedo R, Martín-Antonio B. Hervás-Salcedo R, et al. Cancers (Basel). 2022 Aug 4;14(15):3796. doi: 10.3390/cancers14153796. Cancers (Basel). 2022. PMID: 35954459 Free PMC article. Review. - Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Schwestermann J, Besse A, Driessen C, Besse L. Schwestermann J, et al. Front Oncol. 2022 May 26;12:899272. doi: 10.3389/fonc.2022.899272. eCollection 2022. Front Oncol. 2022. PMID: 35692781 Free PMC article. Review. - Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.
Hathi D, Chanswangphuwana C, Cho N, Fontana F, Maji D, Ritchey J, O'Neal J, Ghai A, Duncan K, Akers WJ, Fiala M, Vij R, DiPersio JF, Rettig M, Shokeen M. Hathi D, et al. Sci Rep. 2022 Jan 7;12(1):30. doi: 10.1038/s41598-021-03748-0. Sci Rep. 2022. PMID: 34996933 Free PMC article. - Pathogenesis and treatment of multiple myeloma bone disease.
Hiasa M, Harada T, Tanaka E, Abe M. Hiasa M, et al. Jpn Dent Sci Rev. 2021 Nov;57:164-173. doi: 10.1016/j.jdsr.2021.08.006. Epub 2021 Sep 23. Jpn Dent Sci Rev. 2021. PMID: 34611468 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous